Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

156
Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
156
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

161
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
161
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

391
Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
391
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

137
Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...
137
Drug Delivery: Overview01:16

Drug Delivery: Overview

1.3K
The selection of a drug's delivery route depends upon its physicochemical properties, including lipid or water solubility and ionization, as well as the therapeutic requirement, such as immediate or sustained effect. These routes can be divided into three primary categories: enteral, parenteral, and topical.
Enteral delivery involves administering drugs directly through swallowing, sublingual placement, or buccal application. Orally administered drugs predominantly navigate the...
1.3K
Modified-Release Drug Delivery Systems: Stimuli-Activated01:30

Modified-Release Drug Delivery Systems: Stimuli-Activated

172
Stimuli-activated drug delivery systems are designed to release drugs in response to specific physical, chemical, or biological stimuli. These systems often utilize hydrogels—three-dimensional, hydrophilic polymer networks capable of swelling in aqueous environments and retaining significant fluid volumes. Upon exposure to particular stimuli, these hydrogels undergo structural transitions that allow the embedded drug to be released. Due to this adaptive behavior, such systems are also...
172

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

mTORC1 signaling requires proteasomal function and the involvement of CUL4-DDB1 ubiquitin E3 ligase.

Cell cycle (Georgetown, Tex.)·2008
Same author

Prospective study of liver transplant recipients with HCV infection: evidence for a causal relationship between HCV and insulin resistance.

Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society·2008
Same author

Quantitative gel electrophoresis: sources of variation.

Journal of proteome research·2008
Same author

Evidence that the Nijmegen breakage syndrome protein, an early sensor of double-strand DNA breaks (DSB), is involved in HIV-1 post-integration repair by recruiting the ataxia telangiectasia-mutated kinase in a process similar to, but distinct from, cellular DSB repair.

Virology journal·2008
Same author

[Inhibitory effects of Qushi Huayu Decoction on fatty deposition and tumor necrosis factor alpha secretion in HepG2 cells induced by free fatty acid].

Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine·2008
Same author

Bioactive polybrominated diphenyl ethers from the marine sponge Dysidea sp.

Journal of natural products·2008

Related Experiment Video

Updated: Apr 28, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.4K

Layered double hydroxide-based nanocarriers for drug delivery.

Xue Bi1, Hui Zhang2, Liguang Dou3

  • 1State Key Laboratory of Chemical Resource Engineering, Beijing University of Chemical Technology, P.O. Box 98, Beijing 100029, China. leospindrift@126.com.

Pharmaceutics
|June 19, 2014
PubMed
Summary

Layered double hydroxides (LDHs) are versatile biocompatible materials for advanced drug delivery systems (DDS). Research shows their potential for controlled release of cardiovascular, anti-inflammatory, and anti-cancer drugs.

More Related Videos

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

9.2K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K

Related Experiment Videos

Last Updated: Apr 28, 2026

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier
10:16

Targeted Plasma Membrane Delivery of a Hydrophobic Cargo Encapsulated in a Liquid Crystal Nanoparticle Carrier

Published on: February 8, 2017

7.4K
Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes
09:47

Facile Preparation of Internally Self-assembled Lipid Particles Stabilized by Carbon Nanotubes

Published on: February 19, 2016

9.2K
Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier
07:53

Encapsulation of Cancer Therapeutic Agent Dacarbazine Using Nanostructured Lipid Carrier

Published on: April 26, 2016

10.2K

Area of Science:

  • Materials Science
  • Biotechnology
  • Nanotechnology

Background:

  • Biocompatible clay materials are increasingly recognized for their potential in efficient drug delivery systems (DDS).
  • Layered double hydroxides (LDHs) represent a promising class of these materials due to their unique layered structure and tunable properties.

Purpose of the Study:

  • To review recent advancements in the application of layered double hydroxides (LDHs) for controlled drug release and delivery.
  • To highlight the influence of synthetic control over intercalated structures and material functionalization on novel applications.
  • To summarize progress in LDH-based DDS for cardiovascular, anti-inflammatory, and anti-cancer therapeutics.

Main Methods:

  • Literature review of research on layered double hydroxides (LDHs) for drug delivery applications.
  • Analysis of studies focusing on the synthesis of intercalated LDH structures.
  • Examination of modification and functionalization strategies for LDH materials.

Main Results:

  • Advances in synthesizing intercalated LDH structures significantly impact the development of new drug delivery applications.
  • Material modification and functionalization open avenues for biotechnological and biomedical uses.
  • LDHs show promise as carriers for cardiovascular, anti-inflammatory, and anti-cancer drugs, enabling controlled release.

Conclusions:

  • Layered double hydroxides (LDHs) are highly promising biocompatible materials for developing advanced drug delivery systems.
  • Tailoring LDH structure and surface properties through synthesis and functionalization is key to unlocking their full therapeutic potential.
  • Further research into LDH-based drug carriers is expected to yield significant innovations in targeted and controlled drug delivery.